Silexion Therapeutics Corp. (NASDAQ: SLXN)* recently released its full-year 2024 financial results and business update, showcasing remarkable progress in its clinical and preclinical programs targeting KRAS-driven cancers. Following these developments,…
Posts published in “Pharma”
A newly published study from the Cleveland Clinic’s Lerner Research Institute has added to the growing body of evidence supporting Nuvectis Pharma’s (NASDAQ: NVCT)* NXP900, a novel SRC/YES1 kinase inhibitor.…
Silexion Therapeutics* (NASDAQ: SLXN) is making strides in oncology with its RNAi-based treatment, SIL-204, targeting KRAS-driven cancers. In an interview on Market Leaders, CEO Ilan Hadar discussed the company’s recent…
DarioHealth (Nasdaq: DRIO)*, a leader in digital health solutions, has taken a bold step into one of healthcare’s fastest-growing markets by enhancing its GLP-1 weight-loss program with virtual prescribing capabilities.…
Nuvectis Pharma (NASDAQ: NVCT) has reported encouraging interim data from its Phase 1b study of NXP800, a drug candidate designed to treat platinum-resistant, ARID1a-mutated ovarian cancer. This type of cancer…